Tuesday, 31 March 2015

New age executive trends

Pharmaceutical firms are increasingly turning their marketing force into teams of specialists, because a generalist medical representative may find it tough to explain to a doctor the complex and high-margin drugs they are pushing.
Pfizer, Sun Pharmaceutical Industries, Abbott, Dr Reddy's Laboratories, Cipla, Lupin, Glenmark Pharmaceuticals, Mankind Pharma, Torrent Pharmaceuticals, Ipca Laboratories and Hetero Drugs are all hiring management and pharmacy graduates as marketing executives and are paying hefty salaries, say industry executives and analysts.
The top 20 companies control at least 40% of the total market and they are in the forefront to recruit specialists. Lupin is one of the pioneers in hiring management graduates and domain experts for sales. More than 80% of its sales force of 4,700 are specialists.
While large pharma companies have hired thousands of management graduates, who account for more than half their sales force, specialist salesmen form less than a third of the teams at many medium firms. Of India's more than six lakh medical representatives, specialists with management education qualifications account for a little over a sixth.
"There is tough competition among domestic and multinational drug makers operating in the Indian market now, which is forcing many to look at hiring specialists like management graduates from top institutes to aggressively push the brands," said Hetero Drugs marketing director M Srinivas Reddy. "Many pharma companies are looking at creating specialist marketing arms with management graduates and domain experts like post-graduates in pharmacy."
Kameshwar Rao of FMRA viewed that the trend of hiring more specialists and management graduates to sell medicines could hurt the financials of small and medium firms that cannot afford heavy overheads.
Source:
 

Monday, 30 March 2015

NIPER - Joint entrance examination 2015

NIPER announces the Joint Entrance Examination for Masters' and Ph.D. Program for 2015. The examination is meant for the admissions for following NIPER institutes.
  • Ahmedabad
  • Guwahati
  • Hajipur
  • Hyderabad
  • Kolkata
  • Raibareli
  • S. A. S. Nagar (Mohali)

 

Pharma academic research - Indian patent applications published on 27th March 2015

Dear All,
Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.
 
We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes.
 
For details of these patents, please write back to us at pharmaliterati@gmail.com
 
Indian patent applications published on 27th March 2015
 
 
Invention
Application No
Inventors
Institute
An anti-leukemic agent useful for inducing differentiation in myeloid
leukemia cells
2807/DEL/2013 A
1) Pal Pooja
2) Lochab Savita
3) Kanuajiya Jitendra Kumar
4) Trivedi Arun Kumar
Council of Scientific & Industrial
Research

Management Aptitude Test - 2015

All Indian Management Association announced the notification for "Management Aptitude Test - 2015".
 
Management Aptitude Test (MAT) is a standardised test being administered since 1988 to facilitate Business Schools (B-Schools) to screen candidates for admission to MBA and allied programmes.
 
Last Date For sale of forms:    18 April 2015 (Saturday).
 
Eligibility:                                    Graduates in any discipline/
                                                    Final year students of Graduate courses can also apply.

 
For a complete List of Participating Management Institutes, please visit:
 
 
 
 
 

Wednesday, 25 March 2015

Goa branch of IPA wins national award

The Goa state branch of the Indian pharmaceutical association (IPA), under the leadership of its president Salim A Veljee, has been awarded the 'Best state branch award 2014' by the Indian pharmaceutical association, central office, Mumbai.

In a communication received by the Goa state branch office, dated March 17, 2015, the IPA congratulated the president and members of the Goa state branch for their "excellent performance of the branch activities and the contributions in supporting the objectives of the association conducted in the larger interest of the pharmaceutical field, and in also maintaining high standards in its activities to the profession of pharmacy."

Veljee thanked the association vice-president Anant Naik for his immense contributions in getting the award. The award will be presented to Veljee and G K Rao, the secretary of the association at the Goa branch and also the principal, Goa college of pharmacy, at the Indian pharmaceutical association annual convention to be held in Mumbai, soon.


http://timesofindia.indiatimes.com/city/goa/Goa-branch-of-IPA-wins-national-award/articleshow/46681832.cms



Tuesday, 24 March 2015

Impact of IT on Indian pharma industry

Dr Subroto Ghoshal, Manager- Human Resources, Mindteck India elaborates on the need to improve connectivity between IT and pharma industry for providing better diagnosis and cost effective treatment to patients in the Financial Express article, which can be accessed here:

http://www.financialexpress.com/article/pharma/management-pharma/impact-of-it-on-indian-pharma-industry/56552/
The article discusses Indian Pharmaceutical Industry's state as on today and the impact of Information technology on the same.

The article discusses:
- Role of IT in pharma industry with some examples like
  • computerised physician order entry (CPOE), 
  • enterprise resource planning (ERP),
  • laboratory information management system (LIMS),
  • customer relationship management (CRM),
  • clinical trial management system (CTMS),
  • sales force automation (SFA),
  • electronic batch records (eBR)
 
- Medical information in pharma industry and the relevance with reference to IT.
- Technology in medical devices.
- Trend in the technology for future pharma industry.
 

Pharma academic research - Indian patent applications published on 20th March 2015

Dear All,
Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.
 
We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes.
 
For details of these patents, please write back to us at pharmaliterati@gmail.com
 
Indian patent applications published on 20th March 2015
 
 
Invention
Application No
Inventors
Institute
A medicinal composition with high chebulinic acid content for cancer
treatment
1121/CHE/2015 A
1) Dr. Meena Vangalapati
2) D.V. Surya Prakash
Associate Professor, Center for
Biotechnology, Department of Chemical Engineering, AUCE (A),
Andhra University
A novel nanocurcumin formulation for ameliorating hypobaric hypoxia
induced maladies
2749/DEL/2013 A
1) Deepika Saraswat
2) Santosh Kar
3) Lilly Ganju
4) Shashi Bala Singh
DTE of ER & IPR group room no. 348, B-Wing, DRDO Bhawan.
Improved coal tar formulation for treatment of dandruff and other scalp
diseases and its method of preparation thereof
2764/DEL/2013 A
1) Bhatia Amit
2) Kapoor Deepak Nandkishore
3) Bangar Baljit
Lovely Professional University


Monday, 23 March 2015

Summer Training at NIPER

Dear All,
          NIPER - Mohali, India's premier pharmacy education institute has announced summer training for 2015.

Departments:

1. Medicinal Chemistry

2. Natural Products

3. Pharmaceutical Analysis

4. Pharmacology and Toxicology

5. Pharmaceutics

6. Biotechnology

7. Pharmacy Practice

8. Pharmaceutical Technology

9. Pharmacoinformatics

10. Pharmaceutical Management
 
Proposed duration of training:                               06 weeks (June 1 to July 15, 2015).

Number of students to be admitted/year:             30 (3 students in each department).

Fees of summer training:                                       Rs. 10,000/- for 6 weeks duration.

Deadline for application:                                        15th April 2015.

Eligibility criteria:

i) Students who are pursuing their post-graduation and have finished their 1st year of post-graduation.

ii) Pursuing post graduation in the field of Pharmaceutical/Chemical/Life Sciences leading to M.Pharm./M.S./M.Sc/M.Tech/M.B.A degree from any recognised Indian University

iii) Certificate from the Head of the Department or Head of the institution mentioning the need of summer training for the student in question.

iv) Curriculum vitae/bio-data of the student.

v) The students need to fill the Application Form for Summer Training available on NIPER website, www.niper.gov.in and furnish all relevant information/documents as mentioned in the application form.
 

 

Thursday, 19 March 2015

India Innovation Initiative 2015

AICTE, DST and CII are jointly organizing India Innovation Initiative 2015 to promote entrepreneurship in the country by sensitizing, encouraging and facilitating innovators for commercialization of their innovations.

 Topics among Life Sciences include,

  • Bio-Informatics
  • Bio-Pharma
  • Bio-Tech
  SN
Activities
Timelines
01
Start Date for Registration
Open
02
Last Date of Receiving Entries for India Innovation Initiative
30th April, 2015
03
Announcement of Short-listed Names
August, 2015
04
i3 National Fair
 
 
Knowledgexpo 2015
October, 2015

 
AWARDS

i3 Award

1. i3 will recognize top 5 innovators and confer them prize money and certificate.

2. Young Indians (Yi) to recognize top 3 young innovators and confer them prize money and certificate

Incubation and Funding support

1. i3 partners to provide incubation support to select i3 participants

2. TIFAC to provide technology refinement and commercialization support to select i3 participants

3. Orientation program for technology commercialization and entrepreneurship at regional fairs

Phd admission notification_NMIMS

Institute: Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, Mumbai.
 
Program & Specialization : Ph.D. in Pharm. Sciences. (Full time)
Pharmaceutics, Pharmacology, Quality Assurance, Pharmaceutical Chemistry / Phyto Chemistry.
 
Last date of online application: 27th June 2015. 
 
Details:
 
 

Wednesday, 18 March 2015

Diabetes link to Rosuvastatin

There is growing evidence that a popular statin carries a particularly high risk of harmful side-effects, a doctor and campaigner has warned. The cholesterol-lowering power of rosuvastatin (Crestor) exceeds all other statins but is also associated with the highest increased risk of diabetes, Dr Sidney Wolfe said.

Writing in the BMJ, the founder and senior adviser to US civil rights group Public Citizen's Health Research Group, said its approval to prevent heart attacks in a very select group of people was based on the results of a study which was stopped early, leading to concern that the treatment effects may have been overestimated.

The drug, which was the most prescribed brand name drug in the US last year, is also a commonly-used statin in the UK. Dr Wolfe said other serious side effects include rhabdomyolysis - a rare condition that causes muscle cells to break down - and renal problems.

Public Citizen asked the US Food and Drug Administration (FDA) to ban the drug in 2004 because of its concerns. "Worldwide 2013 sales were 8.2 billion US dollars (£5.5bn), the third highest for any branded drug," Dr Wolfe writes.

"Given the longstanding, continuing evidence of rosuvastatin's comparative lack of clinical benefits and increasing evidence of risks, how did this happen?  The short answer is that of statins still on the market, the milligram for milligram cholesterol lowering potency of rosuvastatin exceeds all others, a fact exploited in advertising campaigns."

Statins are the most commonly prescribed group of drugs in the NHS with up to 10 million people in England estimated to be taking them.

They are currently offered to people in the UK who have a 20% risk of developing cardiovascular disease within 10 years. But updated guidance from the National Institute for Health and Care Excellence (Nice) last year called for the NHS to widen this to cover people with just a 10% risk.

A spokesman for the Medicines and Healthcare Products Regulatory Agency (MHRA) said: "Statins are safe and effective medicines and play an important role in reducing the risk of heart attack and stroke. Information on possible risks with statins are already contained in the information to prescribers and patients and people should continue to take their medicines as prescribed. If anybody has any questions they should speak to their GP or pharmacist. The MHRA continually reviews the information on the safety of statins and updates the prescribing advice and information for patients where necessary."

http://www.witneygazette.co.uk/news/national/11862320.Diabetes_link_to_popular_statin/


 

Pharma Jan Samadhan’ scheme for redressal of grievances on pricing & availability of drugs

Pharmabiz posts that the National Pharmaceutical Pricing Authority (NPPA) has launched ‘Pharma Jan Samadhan’ scheme for redressal of consumers’ grievances relating to pricing and availability of medicines.

The ‘Pharma Jan Samadhan’ scheme is a web enabled system for redressal of consumers’ grievances. It has put in place a speedy and effective complaint redressal system with respect to availability and pricing of medicines. It would serve as a robust e-governance tool for protection of consumers’ interests through effective implementation of the Drugs (Price Control) Order 2013.

‘Pharma Jan Samadhan’ will provide consumers and others with an on-line facility to redress their complaints relating to over-pricing of medicines, non-availability or shortage of medicines, sale of new medicines without prior price approval of NPPA, and refusal of supply for sale of any medicine without good and sufficient reason.

NPPA will initiate action on any complaint within 48 hours of its receipt. 

The scheme was inaugurated by Union minister of chemicals & fertilizers Ananth Kumar at a function recently. Ananth Kumar also released Compendium of Ceiling Prices of Essential Medicines 2015 prepared by NPPA.

Speaking on the occasion, the minister said that the new initiative shows that the government or NPPA is not only regulator but more of a facilitator. He said that this phama-literacy initiative would create awareness among the people and would act as a deterrence against blackmarketing, spurious medicines, and inflated cost of drugs. Shri Ananth Kumar said that the pharma industry stands on three pillars- quality, availability and affordability, and ‘Pharma Jan Samadhan’ is a step in this direction.
 

New ministry for Pharmaceuticals sector

The government may establish a separate Ministry for the pharmaceuticals sector, which would comprise all departments that deal with issues related to the industry. "For the benefit of end user, the customer and considering the size of industry... There should be a separate Pharma Ministry. Therefore, I, along with Minister of State Hansraj Ahir, will approach Prime Minister and request him to look into this matter," Fertiliser Minister Ananth Kumar said recently.

At present, Central Drugs Standard Control Organisation (CDSCO) and Drug Controller General of India (DGCI), which deal in regulatory control over the import of drugs, approval of new drugs and clinical trials, are governed by Health Ministry.

Whereas, National Pharma Pricing Authority (NPPA), which sets the price limit on essential medicines, comes under Ministry of Chemicals and Fertilisers.

The Minister said that the separate Ministry should work as both facilitator as well as regulator for the sector. "As Prime Minister Narendra Modi created separate Ministry for skill development and Ayush, on the same lines we will request him for separate Pharma Ministry," Kumar added.

Kumar added that the entire pharma sector, which at present is worth Rs 1.8 lakh crore, is based on three pillars - quality, availability and affordability of medicines.

Meanwhile, speaking at the same event, Minister of State for Fertiliser Hansraj Gangaram Ahir said the government is working overtime to ensure the availability of medicines at affordable prices.
 

Thanks all for your support

Dear All,
With all your support and wishes, we have crossed the 100-posts mark and at the same time 1000 page-views mark.

It's pleasure to be associated with you all. Please send your feedback to:
pharmaliterati@gmail.com

Thanks and Regards,
Team Pharma Literati.

Scientists may have uncovered next powerhouse antibiotic in horse dung

Biopharmadive reports that Swiss Scientists may have uncovered next powerhouse antibiotic in horse dung.
 
Summary:
·     European biologists found a bacteria-killing compound in mushrooms that grows in horse dung—and it's a protein known as copsin. 
·     Copsin has the same effects on bacteria as traditional antibiotics.
·     The research team is led by Markus Aebi and is based at the Swiss Federal Institute of Technology in Zurich.
The excitement that copsin has caused is based on many factors, including the fact that antibiotic-resistant infections are on the rise and becoming increasingly deadly. Scientists have been working with a great deal of determination to find treatments for diseases, such as tuberculosis. 
Copsin is unique in that it is a protein and most antibiotics are non-protein organic compounds. Nonetheless, copsin has the sought-after qualities that make any substance with antibiotic potential desirable. Copsin is a very stable protein that can withstand intense heat and exposure to acid. It can also be treated with aggressive enzymes and remain completely active. 
Plus, given the fact that it grows in common mushrooms in horse manure, it's sufficiently copious. This makes it ideal for applications in the food industry. Dr. Aebi and his team have registered copsin for patent approval. 
 
 

Monday, 16 March 2015

Is overuse of antibiotics driving up rates of ulcers, stomach cancer, allergies, asthma and obesity?

Martin J. Blaser, the director of the Human Microbiome Program at NYU takes on this question in his book "Missing Microbes: How the Overuse of Antibiotics Is Fueling our Modern Plagues".

Q: What made you initially wonder if H. pylori were not always harmful, or that it might be beneficial? When did you suspect it might be a case of amphibiosis?
Ans: The more that I thought that Hp was really ancient, I asked whether an organism that has been around for such a long time might also have benefit to us. As we started studying diseases of the esophagus we found evidence supporting a protective role for Hp, thus it could be beneficial as well as harmful. The bottom line is that Hp may be costly to us in terms of stomach diseases but it is beneficial in terms esophageal diseases.

Q: The relationship between a stomach microbe and GI issues like heartburn and ulcers seems logical, but you found some extraordinary correlations between H. pylori and protection against other health problems. Can you share your findings? How can a stomach microbe impact asthma?
Ans: When Hp is present in the stomach, there is a rich response in the stomach wall involving many immune cells—T-cells and B-cells. Some of these include T-reg cells. We now know that the Hp+ stomach has many more T-reg cells than the Hp- stomach. We believe that these have a global role in setting immunological tone, rather than just a local role.

Q: What do we know about how H. pylori impacts appetite regulation, height and obesity?
Ans: The stomach also produces hormones involved in energy storage and expenditure—hormones known as leptin and ghrelin. Most of the body’s ghrelin is produced in the stomach—and Hp appears to play a role in ghrelin metabolism. We and others have provided evidence that Hp may be involved in the regulation of these hormones that in turn regulate energy flux. These effects could have bearing on appetite, height and weight.

Q: Why is H. pylori becoming less common in humans, and how do factors like smaller family sizes impact that trend? Do we know enough yet to know if it would be harmful if H. pylori disappeared in humans?
Ans: I believe that we already know two harms: more esophageal diseases and more childhood-onset asthma. 

Q: Despite peer-reviewed publications by you and others, some doctors and scientists still view H. pylori purely as a pathogen. What do you think is the majority view on Hp at this stage, and why has there been resistance to change in the medical community?
Generally speaking, which professional communities tend to agree with you or remain open to your work and which tend to dismiss your work? Do you feel the pharmaceutical industry has played a role in that?
Ans: Gastroenterologists in general are still operating on the notion that Hp is only a pathogen. Specialists in infectious diseases, and especially microbiologists and ecologists have a much more balanced view. But the gastroenterologists are seeing most of the patients, and they are the opinion leaders in this area of medicine.

Q: Given that your views are considered controversial, what are some the critiques of your work on H. pylori, and how do you respond to them?
Ans: One critique is that my ideas are true but not important enough in light of the known risks of ulcer disease and stomach cancer. Another view is that we have shown associations but not cause. My responses are to be as accurate as possible about the possible benefits of eradicating Hp, and about the costs. Ultimately, truth will win out. From an ecological viewpoint, my ideas are well-founded, and I believe that biology always trumps clinical fashion

Q: What do you think your findings about H. pylori mean for human understanding of microbes in general? Is there a larger lesson to take away from this as we begin to understand our relationship with other microbes that live inside of us?
Ans: Yes, our ancient bacteria come with cost but they also provide benefit; we need to look at both sides of the story.

Read the entire interview at: http://www.rawstory.com/rs/2015/03/is-overuse-of-antibiotics-driving-up-rates-of-ulcers-stomach-cancer-allergies-asthma-and-obesity/